Asset profile
PT-112
Small molecule
Evidence outlook · lead readout
NCT03409458 · Non-Small Cell Lung Cancer (NSCLC)
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT03409458: The study treated 68 participants in a single open-label group without randomization or a comparator arm. Its primary endpoint was overall tumor response by iRECIST, but no results have been posted, so the treatment effect cannot be assessed.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.